(Q40562646)

21 September 2017

title

EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer (English)

1 reference

21 September 2017

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26349474%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

Kyoko Otsuka

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26349474%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Akito Hata

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26349474%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Jumpei Takeshita

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26349474%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Chiyuki Okuda

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26349474%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Reiko Kaji

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26349474%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Katsuhiro Masago

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26349474%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Nobuyuki Katakami

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26349474%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

language of work or name

1 reference

8 September 2015

1 reference

Cancer Chemotherapy and Pharmacology

21 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26349474%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

volume

76

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26349474%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26349474%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

835-841

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26349474%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00280-015-2867-8

2 June 2020

exact match

0 references

cites work

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

Rociletinib in EGFR-mutated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

Phase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

Prospective study of gefitinib readministration after chemotherapy in patients with advanced non-small-cell lung cancer who previously responded to gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

Does T790M disappear? Successful gefitinib rechallenge after T790M disappearance in a patient with EGFR-mutant non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

Complex Mutations in the Epidermal Growth Factor Receptor Gene in Non-small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

Do complex mutations of the epidermal growth factor receptor gene reflect intratumoral heterogeneity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non-Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2867-8

10.1007/S00280-015-2867-8

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26349474%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

2 June 2020

1045466676

0 references

Fatcat ID

release_a4hhy32a5nhrxfnswuhb34rlyu

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/a4hhy32a5nhrxfnswuhb34rlyu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference